AACR: LY2835219 promising for metastatic breast cancer

AACR: LY2835219 promising for metastatic breast cancer

(HealthDay)—The novel cell cycle inhibitor selective for the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6), LY2835219, shows promise for metastatic breast cancer, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 9 in San Diego.

Amita Patnaik, M.D., from South Texas Accelerated Research Therapeutics in San Antonio, and colleagues conducted a phase I study with expansion cohorts to assess the safety, pharmacokinetics, and of LY2835219 in five tumor types. LY2835219 was administered to the expansion cohorts (132 patients) every 12 hours on days one to 28 of a 28-day cycle.

The researchers found that, across expansion cohorts, the most common possibly related treatment-emergent adverse events included diarrhea, nausea, fatigue, vomiting, and neutropenia. Forty-seven patients with received LY2835219 therapy, nine of whom achieved a best overall response or confirmed partial response, 24 achieved stable disease, 11 had progressive disease, and three were not evaluable for response. Nine of the 36 hormone receptor-positive (HR+) patients had confirmed partial responses, and 20 (56 percent) had stable disease. The disease control rate was 70 percent for all and 81 percent for those with HR+ disease.

"When tested on various types in preclinical studies, HR+ cells were found to be highly sensitive to this drug," Patnaik said in a statement.

One author disclosed financial ties to Eli Lilly, which developed LY2835219 and funded the study.

More information: Press Release
More Information

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Elucidating the origin of MDR tuberculosis strains

1 hour ago

A study has focused on the evolutionary history of the mycobacterium that causes tuberculosis, and more specifically on the Beijing lineage associated with the spread of multidrug resistant forms of the disease ...

Mexico escalating the fight against breast cancer

3 hours ago

On Avenue San Fernando, a tree-lined street crowded with food stands, the new wing of Mexico's flagship cancer hospital gleams like a silver airplane. Barely a year old, the light-filled structure attached to the National ...

Core needle biopsy helpful with cervical lymphadenopathy

19 hours ago

(HealthDay)—Core needle biopsy (CNB) is a more sensitive tool than fine-needle aspiration cytology (FNAC) for cervical lymphadenopathy evaluation, according to a study published in the February issue of ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.